RecruitingNCT04230785

Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)

Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)


Sponsor

Nanjing First Hospital, Nanjing Medical University

Enrollment

300 participants

Start Date

Mar 15, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and/or after endovascular treatment. The candidate circRNA/lncRNA/miRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating small RNA molecules (called non-coding RNAs) that circulate in the blood of people who have had an acute ischemic stroke and been treated with endovascular therapy (a procedure to physically remove or dissolve the blood clot blocking a brain artery). After a stroke, certain biological signals are released into the bloodstream, and researchers believe non-coding RNAs could serve as diagnostic or prognostic biomarkers — helping doctors predict recovery or select treatments. Blood samples are collected at multiple time points before and after the procedure to track how these RNA levels change. Identifying reliable stroke biomarkers could eventually lead to better, more personalized stroke care. You may be eligible if: - You are between 18 and 90 years old - You have been diagnosed with an acute ischemic stroke confirmed by MRI or CT - Your stroke occurred within the past 24 hours - You are being treated with endovascular therapy You may NOT be eligible if: - You have a history of hemorrhagic stroke - You have chronic kidney or liver disease - You have peripheral artery occlusive disease - You have an active malignant disease - You have inflammatory or infectious diseases Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICSequencing of circRNA/lncRNA/miRNA

Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)


Locations(1)

Nanjing First Hospital, Nanjing Medical University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04230785


Related Trials